Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
出版年份 2016 全文链接
标题
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
作者
关键词
-
出版物
Nature Reviews Endocrinology
Volume 12, Issue 10, Pages 566-592
出版商
Springer Nature
发表日期
2016-06-26
DOI
10.1038/nrendo.2016.86
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial
- (2016) Michael Nauck et al. DIABETES CARE
- Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
- (2016) John P. Bilezikian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
- (2016) Nelson B. Watts et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment
- (2015) Heidi Storgaard et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future
- (2015) CJ Bailey CLINICAL PHARMACOLOGY & THERAPEUTICS
- Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
- (2015) Feng Sun et al. CLINICAL THERAPEUTICS
- Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus
- (2015) Christopher S. Kovacs et al. CLINICAL THERAPEUTICS
- Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
- (2015) Juris J. Meier et al. DIABETES CARE
- Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
- (2015) Luc Van Gaal et al. DIABETES CARE
- Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)
- (2015) Francesco Giorgino et al. DIABETES CARE
- Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
- (2015) Ngozi Erondu et al. DIABETES CARE
- Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5
- (2015) John B. Buse et al. DIABETES CARE
- Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Giulia Ferrannini et al. DIABETES CARE
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Anne L. Peters et al. DIABETES CARE
- Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
- (2015) Julio Rosenstock et al. DIABETES CARE
- Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension
- (2015) N. B. Amin et al. DIABETES OBESITY & METABOLISM
- Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin
- (2015) N. B. Amin et al. DIABETES OBESITY & METABOLISM
- Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials
- (2015) M. Reaney et al. DIABETES OBESITY & METABOLISM
- Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study
- (2015) R. S. Weinstock et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
- (2015) T. Karagiannis et al. DIABETES OBESITY & METABOLISM
- One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial
- (2015) S. C. L. Gough et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial
- (2015) A. Ahmann et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes
- (2015) G. Fulcher et al. DIABETES OBESITY & METABOLISM
- Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial
- (2015) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials
- (2015) Pavel S. Roshanov et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
- (2015) Feng Sun et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes
- (2015) Hans-Ulrich Haering et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Empagliflozin as add-on to metformin in people with Type 2 diabetes
- (2015) L. Merker et al. DIABETIC MEDICINE
- Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial
- (2015) Wolfgang Kothny et al. DIABETOLOGIA
- DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP–glucagon counterregulatory axis in mice
- (2015) Siri Malmgren et al. DIABETOLOGIA
- The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis
- (2015) Emma O. Billington et al. DIABETOLOGIA
- Trelagliptin: First Global Approval
- (2015) Kate McKeage DRUGS
- Omarigliptin: First Global Approval
- (2015) Celeste B. Burness DRUGS
- Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
- (2015) Ele Ferrannini et al. EUROPEAN HEART JOURNAL
- Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review
- (2015) Shashank R Joshi et al. EXPERT OPINION ON PHARMACOTHERAPY
- Efficacy and Safety of Bromocriptine-QR in Type 2 Diabetes: A Systematic Review and Meta-Analysis
- (2015) W. Liang et al. HORMONE AND METABOLIC RESEARCH
- Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study
- (2015) Ann V. Schwartz et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study
- (2015) Yuhao Huang et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study
- (2015) Lawrence Blonde et al. LANCET
- Five-Year Efficacy and Safety Data of Exenatide Once Weekly
- (2015) Carol H. Wysham et al. MAYO CLINIC PROCEEDINGS
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
- (2015) Caroline Bonner et al. NATURE MEDICINE
- Islet α cells and glucagon—critical regulators of energy homeostasis
- (2015) Jonathan E. Campbell et al. Nature Reviews Endocrinology
- Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Rodney A. Hayward et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients
- (2015) K. Esposito et al. BMJ Open
- Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study
- (2015) Nobuya Inagaki et al. Lancet Diabetes & Endocrinology
- Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study
- (2015) Szu-Chun Hung et al. Lancet Diabetes & Endocrinology
- Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study
- (2015) Hiroaki Ueno et al. Diabetes Therapy
- Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study
- (2015) Hiroaki Ueno et al. Diabetes Therapy
- Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
- (2015) Sri Harsha Tella et al. Therapeutic Advances in Endocrinology and Metabolism
- The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis
- (2015) Jessica E. Potts et al. PLoS One
- Comparative Efficacy and Safety of Antidiabetic Drug Regimens Added to Metformin Monotherapy in Patients with Type 2 Diabetes: A Network Meta-Analysis
- (2015) Elizabeth S. Mearns et al. PLoS One
- Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial
- (2014) Rury R. Holman et al. AMERICAN HEART JOURNAL
- Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus
- (2014) André J. Scheen CLINICAL PHARMACOKINETICS
- Safety of Metformin in Patients with Chronic Obstructive Pulmonary Disease and Type 2 Diabetes Mellitus
- (2014) Andrew W. Hitchings et al. COPD-Journal of Chronic Obstructive Pulmonary Disease
- Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
- (2014) Paul Nyirjesy et al. CURRENT MEDICAL RESEARCH AND OPINION
- Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study
- (2014) Tanja Dujic et al. DIABETES
- Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?
- (2014) Philip Home et al. DIABETES CARE
- Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro
- (2014) Julio Rosenstock et al. DIABETES CARE
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)
- (2014) John B. Buse et al. DIABETES CARE
- The Pharmacogenetics of Type 2 Diabetes: A Systematic Review
- (2014) Nisa M. Maruthur et al. DIABETES CARE
- Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study
- (2014) Lawrence A. Leiter et al. DIABETES CARE
- Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes
- (2014) Bruce Neal et al. DIABETES CARE
- HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin
- (2014) Bo Ahrén et al. DIABETES CARE
- Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
- (2014) Hans-Ulrich Häring et al. DIABETES CARE
- Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)
- (2014) Guillermo Umpierrez et al. DIABETES CARE
- Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
- (2014) Carol Wysham et al. DIABETES CARE
- Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
- (2014) Michael Nauck et al. DIABETES CARE
- Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
- (2014) Julio Rosenstock et al. DIABETES CARE
- Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
- (2014) Ilkka Tikkanen et al. DIABETES CARE
- Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1 324 515 patients from observational studies
- (2014) T. Wang et al. DIABETES OBESITY & METABOLISM
- Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin
- (2014) M. A. Nauck et al. DIABETES OBESITY & METABOLISM
- A systematic review and meta-analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes
- (2014) L. J. Schmidt et al. DIABETES OBESITY & METABOLISM
- Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5
- (2014) P. D. Home et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled
- (2014) J. Reusch et al. DIABETES OBESITY & METABOLISM
- Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin
- (2014) S. Grandy et al. DIABETES OBESITY & METABOLISM
- Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials
- (2014) B. Ahrén et al. DIABETES OBESITY & METABOLISM
- Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5)
- (2014) Z. Skrivanek et al. DIABETES OBESITY & METABOLISM
- Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis
- (2014) Y. G. Kim et al. DIABETES OBESITY & METABOLISM
- Novel therapeutics for type 2 diabetes: insulin resistance
- (2014) Q.-A. Altaf et al. DIABETES OBESITY & METABOLISM
- Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus
- (2014) S. Sha et al. DIABETES OBESITY & METABOLISM
- Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia)
- (2014) Chang Yu Pan et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes
- (2014) Denis Raccah et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub-study of the DREAM trial
- (2014) Z. Punthakee et al. DIABETIC MEDICINE
- Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin
- (2014) Heike Zimdahl et al. DIABETOLOGIA
- HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea
- (2014) Peter N. Weissman et al. DIABETOLOGIA
- Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events
- (2014) Agata Ptaszynska et al. DRUG SAFETY
- Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
- (2014) André J. Scheen DRUGS
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis
- (2014) Xu-Ping Yang et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Empagliflozin for the treatment of type 2 diabetes
- (2014) Vidhya Jahagirdar et al. EXPERT OPINION ON PHARMACOTHERAPY
- Efficacy and Safety of Colesevelam in Combination with Pioglitazone in Patients with Type 2 Diabetes Mellitus
- (2014) J. Rosenstock et al. HORMONE AND METABOLIC RESEARCH
- Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus
- (2014) Keith C. Ferdinand et al. HYPERTENSION
- A Randomized Controlled Trial of the Effects of Pioglitazone Treatment on Sympathetic Nervous System Activity and Cardiovascular Function in Obese Subjects With Metabolic Syndrome
- (2014) Nora E. Straznicky et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
- (2014) Aurora Merovci et al. JOURNAL OF CLINICAL INVESTIGATION
- Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis
- (2014) Bernard Charbonnel et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in Type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)
- (2014) Julio Rosenstock et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes
- (2014) Tesfaye Biftu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
- (2014) Kathleen M Dungan et al. LANCET
- Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis
- (2014) Conrad Eng et al. LANCET
- Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial
- (2014) Peter Stein et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
- (2014) Anila K. Madiraju et al. NATURE
- Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
- (2014) Amy G. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Target of Metformin in Type 2 Diabetes
- (2014) Ele Ferrannini NEW ENGLAND JOURNAL OF MEDICINE
- Metformin in Chronic Kidney Disease: Time for a Rethink
- (2014) J. Heaf PERITONEAL DIALYSIS INTERNATIONAL
- Inhibition of HDAC3 as a strategy for developing novel diabetes therapeutics
- (2014) Bennett C Meier et al. Epigenomics
- The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials
- (2014) Yu-nan Sun et al. BMJ Open
- Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials
- (2014) K. Esposito et al. BMJ Open
- Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies
- (2014) L. Li et al. BMJ-British Medical Journal
- Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
- (2014) Richard E Pratley et al. Lancet Diabetes & Endocrinology
- Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial
- (2014) Michaela Diamant et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes
- (2014) Stephen C L Gough et al. Lancet Diabetes & Endocrinology
- Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
- (2014) Martin Ridderstråle et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
- (2014) Anthony H Barnett et al. Lancet Diabetes & Endocrinology
- Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus
- (2014) Kira B. Harris et al. Therapeutic Advances in Endocrinology and Metabolism
- GLP-1 receptor agonists: a review of head-to-head clinical studies
- (2014) Jennifer M. Trujillo et al. Therapeutic Advances in Endocrinology and Metabolism
- Results of a reevaluation of cardiovascular outcomes in the RECORD trial
- (2013) Kenneth W. Mahaffey et al. AMERICAN HEART JOURNAL
- Effect of GLP-1 Mimetics on Blood Pressure and Relationship to Weight Loss and Glycemia Lowering: Results of a Systematic Meta-Analysis and Meta-Regression
- (2013) M. Katout et al. AMERICAN JOURNAL OF HYPERTENSION
- Efficacy and Safety of Sitagliptin in Patients With Type 2 Diabetes and ESRD Receiving Dialysis: A 54-Week Randomized Trial
- (2013) Juan C. Arjona Ferreira et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes
- (2013) John B. Buse et al. ANNALS OF INTERNAL MEDICINE
- State of the art paper The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus
- (2013) Rodolfo Guardado-Mendoza et al. Archives of Medical Science
- Comparative Safety and Effectiveness of Metformin in Patients With Diabetes Mellitus and Heart Failure
- (2013) Dean T. Eurich et al. Circulation-Heart Failure
- Reponse to Comments on: Butler et al. Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors. Diabetes 2013;62:2595-2604
- (2013) A. E. Butler et al. DIABETES
- Metformin revisited: A critical review of the benefit–risk balance in at-risk patients with type 2 diabetes
- (2013) A.J. Scheen et al. DIABETES & METABOLISM
- Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus
- (2013) D.R. Owens et al. DIABETES & METABOLISM
- Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
- (2013) J. Rosenstock et al. DIABETES CARE
- Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes
- (2013) Robert R. Henry et al. DIABETES CARE
- Interpreting Adverse Signals in Diabetes Drug Development Programs
- (2013) C. J. Bailey DIABETES CARE
- Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)
- (2013) Bo Ahrén et al. DIABETES CARE
- Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
- (2013) H.-U. Haring et al. DIABETES CARE
- Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin
- (2013) Matthew C. Riddle et al. DIABETES CARE
- Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine
- (2013) Matthew C. Riddle et al. DIABETES CARE
- Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)
- (2013) M. Pinget et al. DIABETES OBESITY & METABOLISM
- Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study
- (2013) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
- (2013) T. Heise et al. DIABETES OBESITY & METABOLISM
- Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
- (2013) C. S. Kovacs et al. DIABETES OBESITY & METABOLISM
- A Randomized, Double-Blind, Comparative Therapy Evaluating Sitagliptin Versus Glibenclamide in Type 2 Diabetes Patients Already Treated with Pioglitazone and Metformin: A 3-Year Study
- (2013) Giuseppe Derosa et al. Diabetes Technology & Therapeutics
- Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials
- (2013) Yifei Zhang et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)
- (2013) G. B. Bolli et al. DIABETIC MEDICINE
- Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis
- (2013) Y. G. Kim et al. DIABETOLOGIA
- Efficacy of Anthiyperglycemic Therapies and the Influence of Baseline Hemoglobin A1C: A Meta-Analysis of the Liraglutide Development Program
- (2013) Robert Henry et al. Endocrine Practice
- Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
- (2013) André J Scheen Expert Opinion on Drug Metabolism & Toxicology
- Cardiovascular effects of gliptins
- (2013) André J. Scheen Nature Reviews Cardiology
- Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties
- (2013) P. Arnouts et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT inhibitors in management of diabetes
- (2013) Abd A Tahrani et al. Lancet Diabetes & Endocrinology
- Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
- (2013) Michael Roden et al. Lancet Diabetes & Endocrinology
- Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial
- (2013) Wenying Yang et al. Lancet Diabetes & Endocrinology
- Drug-Drug Interactions with Glucagon-Like Peptide-1 Receptor Agonists
- (2012) Kathryn M Hurren et al. ANNALS OF PHARMACOTHERAPY
- Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis
- (2012) Haesuk Park et al. ANNALS OF PHARMACOTHERAPY
- Metformin affects the circadian clock and metabolic rhythms in a tissue-specific manner
- (2012) Maayan Barnea et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Mechanisms for Insulin Resistance: Common Threads and Missing Links
- (2012) Varman T. Samuel et al. CELL
- Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
- (2012) Vanita R. Aroda et al. CLINICAL THERAPEUTICS
- Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes
- (2012) J. Rosenstock et al. DIABETES CARE
- Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas
- (2012) M. Davies et al. DIABETES CARE
- Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency
- (2012) J. C. Arjona Ferreira et al. DIABETES CARE
- Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
- (2012) V. A. Fonseca et al. DIABETES CARE
- Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis
- (2012) C. F. Deacon et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin
- (2012) Ö. Ljunggren et al. DIABETES OBESITY & METABOLISM
- Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)
- (2012) Y. Seino et al. DIABETES OBESITY & METABOLISM
- Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin
- (2012) D. Devineni et al. DIABETES OBESITY & METABOLISM
- Cardiovascular Biology of the Incretin System
- (2012) John R. Ussher et al. ENDOCRINE REVIEWS
- A randomized placebo controlled double blind crossover study of pioglitazone on left ventricular diastolic function in type 2 diabetes
- (2012) Alun David Hughes et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Vildagliptin Reduces Glucagon during Hyperglycemia and Sustains Glucagon Counterregulation during Hypoglycemia in Type 1 Diabetes
- (2012) Johan Farngren et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
- (2012) Baptist Gallwitz et al. LANCET
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
- (2012) John B Buse et al. LANCET
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- Cellular and molecular mechanisms of metformin: an overview
- (2011) Benoit Viollet et al. CLINICAL SCIENCE
- Antidiabetic Agents in Patients with Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: Metabolism and Clinical Practice
- (2011) Masanori Abe et al. CURRENT DRUG METABOLISM
- Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study
- (2011) D. Russell-Jones et al. DIABETES CARE
- Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial
- (2011) M. A. Nauck et al. DIABETES CARE
- Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials
- (2011) Y. Wang et al. DIABETES OBESITY & METABOLISM
- A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes
- (2011) P. Barrington et al. DIABETES OBESITY & METABOLISM
- Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
- (2011) R. Grempler et al. DIABETES OBESITY & METABOLISM
- Mechanisms Underlying Metformin-Induced Secretion of Glucagon-Like Peptide-1 from the Intestinal L Cell
- (2011) Andrew J. Mulherin et al. ENDOCRINOLOGY
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
- (2011) Jacob Lønborg et al. EUROPEAN HEART JOURNAL
- Pramlintide and the treatment of diabetes: a review of the data since its introduction
- (2011) Lisa M Younk et al. EXPERT OPINION ON PHARMACOTHERAPY
- A clinical risk score for heart failure in patients with type 2 diabetes and macrovascular disease: An analysis of the PROactive study
- (2011) Roman Pfister et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
- (2011) Thomas Blevins et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Management of type 2 diabetes: new and future developments in treatment
- (2011) Abd A Tahrani et al. LANCET
- Biology of Human Sodium Glucose Transporters
- (2011) Ernest M. Wright et al. PHYSIOLOGICAL REVIEWS
- Renal glucose reabsorption inhibitors to treat diabetes
- (2011) Clifford J. Bailey TRENDS IN PHARMACOLOGICAL SCIENCES
- Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study
- (2010) Anne Gill et al. Cardiovascular Diabetology
- Dipeptidylpeptitase-4 Inhibitors (Gliptins)
- (2010) André J. Scheen CLINICAL PHARMACOKINETICS
- Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?
- (2010) Mikkel Christensen et al. Current Diabetes Reports
- Hypothalamic AMP-Activated Protein Kinase Regulates Glucose Production
- (2010) C. S. Yang et al. DIABETES
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
- (2010) E. Ferrannini et al. DIABETES CARE
- Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes
- (2010) J. M. Gaziano et al. DIABETES CARE
- DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
- (2010) J. B. Buse et al. DIABETES CARE
- Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study
- (2010) D. R. Matthews et al. DIABETES OBESITY & METABOLISM
- Bromocriptine: old drug, new formulation and new indication
- (2010) R. I. G. Holt et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
- (2010) C. F. Deacon DIABETES OBESITY & METABOLISM
- Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes
- (2010) A. Garber et al. DIABETES OBESITY & METABOLISM
- Effect of Repaglinide Versus Glyburide on Postprandial Glucose and Insulin Values in Elderly Patients with Type 2 Diabetes
- (2010) Graydon S. Meneilly Diabetes Technology & Therapeutics
- Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
- (2010) André J. Scheen et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study
- (2010) C. Filozof et al. DIABETIC MEDICINE
- Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
- (2010) R. E. Ratner et al. DIABETIC MEDICINE
- Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia
- (2010) A. Bellomo Damato et al. DIABETIC MEDICINE
- Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice
- (2010) A. Maida et al. DIABETOLOGIA
- New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser
- (2010) Y. M. Cho et al. DIABETOLOGIA
- Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
- (2010) M. A. Nauck et al. DIABETOLOGIA
- Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
- (2010) T. Seck et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
- (2010) Michaela Diamant et al. LANCET
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes
- (2010) Biliana Marcheva et al. NATURE
- Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Drug evaluation: Vildagliptin-metformin single-tablet combination
- (2009) Abd A. Tahrani et al. ADVANCES IN THERAPY
- Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
- (2009) Abd A. Tahrani et al. ADVANCES IN THERAPY
- Glucose transporters in the 21st Century
- (2009) Bernard Thorens et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
- (2009) R. A. DeFronzo DIABETES
- Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
- (2009) B. Zinman et al. DIABETES CARE
- Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing
- (2009) J. Rosenstock et al. DIABETES CARE
- Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence
- (2009) Vivian A. Fonseca et al. DIABETES OBESITY & METABOLISM
- Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
- (2009) M. Marre et al. DIABETIC MEDICINE
- Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene
- (2009) H. Mulder et al. DIABETOLOGIA
- Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
- (2009) D. Russell-Jones et al. DIABETOLOGIA
- In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans
- (2009) M. Obermeier et al. DRUG METABOLISM AND DISPOSITION
- Efficacy and Safety Comparison Between the DPP-4 Inhibitor Vildagliptin and the Sulfonylurea Gliclazide After Two Years of Monotherapy in Drug-naïve Patients with Type 2 Diabetes
- (2009) J. E. Foley et al. HORMONE AND METABOLIC RESEARCH
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- Glycaemic control in type 2 diabetes: Targets and new therapies
- (2009) Abd A. Tahrani et al. PHARMACOLOGY & THERAPEUTICS
- CNS Regulation of Glucose Homeostasis
- (2009) Carol K. L. Lam et al. PHYSIOLOGY
- DPP-4 Inhibitors in Clinical Practice
- (2009) Anna I. Palalau et al. POSTGRADUATE MEDICINE
- Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
- (2008) Y. K. Loke et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- New treatments in type 2 diabetes: a focus on the incretin-based therapies
- (2008) Anthony H. Barnett CLINICAL ENDOCRINOLOGY
- Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
- (2008) David C. Klonoff et al. CURRENT MEDICAL RESEARCH AND OPINION
- Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes
- (2008) J.-F. Gautier et al. DIABETES & METABOLISM
- Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
- (2008) M. Nauck et al. DIABETES CARE
- Treatment intensification in patients with type 2 diabetes
- (2008) Anthony H. Barnett DIABETES OBESITY & METABOLISM
- Metformin and the intestine
- (2008) C. J. Bailey et al. DIABETOLOGIA
- Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes
- (2008) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes
- (2008) Jessica E. Matthews et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
- (2008) Wei Meng et al. JOURNAL OF MEDICINAL CHEMISTRY
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
- Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
- (2008) Alan Garber et al. LANCET
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
- (2008) William Duckworth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-nave elderly patients with type 2 diabetes
- (2007) S. L. Schwarz et al. DIABETES OBESITY & METABOLISM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search